Company size20–49 employees
Company profileAbout NuVision BiotherapiesLocated in Nottingham, NuVision Biotherapies is a tissue-therapy company that is based on 15 years of translational research at the University of Nottingham. The business was founded in 2015 with investment from Mercia Fund Management.NuVision develops and provides a selection of products that pioneer therapies in ophthalmology. The Tereo Process is an established, dual patented manufacturing process that enables the scalable production of amniotic membrane processing.Omnigen is NuVision’s ocular-specific Tereo processed amniotic membrane product, originating from the innermost layer of the placental sac that protects the foetus during pregnancy. Omnigen is processed using Tereo, therefore the product retains its natural tissue quality to preserve its barrier function and structural integrity. Omnigen can be directly applied to the ocular surface and therefore no preparation time is required prior to use. Omnigen is currently available in 140 UK hospitals, 30 UK private hospitals and seven countries.NuVision also provides OmniLenz, a specialised bandage for the in-office application of Omnigen in a four to six minute procedure. The product is currently available in three sizes, allowing healthcare professionals to make a clinical decision on the version of the treatment they offer.
